| 1 |
Chakraborty C, Bhattacharya M, Dhama K. SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. Vaccines 2023;11:682. [DOI: 10.3390/vaccines11030682] [Reference Citation Analysis]
|
| 2 |
Mantovani A, Rescigno M, Forni G, Tognon F, Putoto G, Ictho J, Lochoro P. COVID-19 vaccines and a perspective on Africa. Trends Immunol 2023;44:172-87. [PMID: 36709083 DOI: 10.1016/j.it.2023.01.005] [Reference Citation Analysis]
|
| 3 |
Chavda VP, Baviskar KP, Vaghela DA, Raut SS, Bedse AP. Nasal sprays for treating COVID-19: a scientific note. Pharmacol Rep 2023;:1-17. [PMID: 36848033 DOI: 10.1007/s43440-023-00463-7] [Reference Citation Analysis]
|
| 4 |
Dodaran MS, Banihashemi SR, Es-Haghi A, Mehrabadi MHF, Nofeli M, Mokarram AR, Mokhberalsafa L, Sadeghi F, Ranjbar A, Ansarifar A, Mohazzab A, Setarehdan SA, Bagheri Amiri F, Mohseni V, Hajimoradi M, Ghahremanzadeh N, Razzaz SH, Masoomi S, Taghdiri M, Bagheri M, Lofti M, Khorasani A, Ghader M, Safari S, Shahsavn M, Kalantari S. Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial. Vaccines (Basel) 2023;11. [PMID: 36851334 DOI: 10.3390/vaccines11020455] [Reference Citation Analysis]
|
| 5 |
Nakahashi-Ouchida R, Fujihashi K, Kurashima Y, Yuki Y, Kiyono H. Nasal vaccines: solutions for respiratory infectious diseases. Trends Mol Med 2023;29:124-40. [PMID: 36435633 DOI: 10.1016/j.molmed.2022.10.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Shahnoor S, Priya P, Khatri G. Intranasal COVID-19 vaccine: a modern vaccination approach. Int J Surg 2023;109:43-4. [PMID: 36799789 DOI: 10.1097/JS9.0000000000000046] [Reference Citation Analysis]
|
| 7 |
Santos ACF, Martel F, Freire CSR, Ferreira BJML. Polymeric Materials as Indispensable Tools to Fight RNA Viruses: SARS-CoV-2 and Influenza A. Bioengineering (Basel) 2022;9. [PMID: 36551022 DOI: 10.3390/bioengineering9120816] [Reference Citation Analysis]
|
| 8 |
Chavda VP, Soni S, Vora LK, Soni S, Khadela A, Ajabiya J. mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics. Vaccines (Basel) 2022;10. [PMID: 36560560 DOI: 10.3390/vaccines10122150] [Reference Citation Analysis]
|
| 9 |
Wang S, Xu L, Mu T, Qin M, Zhao P, Xie L, Du L, Wu Y, Legrand N, Mouchain K, Fichet G, Liu Y, Yin W, Zhao J, Ji M, Gong B, Klein M, Wu K. Intranasal delivery of a chimpanzee adenovirus vector expressing a pre-fusion spike (BV-AdCoV-1) protects golden Syrian hamsters against SARS-CoV-2 infection. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.979641] [Reference Citation Analysis]
|
| 10 |
Baklaushev VP, Yusubalieva GM, Bychinin MV, Yusubalieva SM, Kalsin VA, Troitskiy AV. A rational strategy for the maintenance of antiviral immunity to new SARS-CoV-2 strains. Journal of Clinical Practice 2022;13:43-55. [DOI: 10.17816/clinpract111120] [Reference Citation Analysis]
|
| 11 |
Murphy RL, Paramithiotis E, Sugden S, Chermak T, Lambert B, Montamat-sicotte D, Mattison J, Steinhubl S. The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials. Front Immunol 2022;13:923106. [DOI: 10.3389/fimmu.2022.923106] [Reference Citation Analysis]
|
| 12 |
Gu Y, Duan J, Yang N, Yang Y, Zhao X. mRNA vaccines in the prevention and treatment of diseases. MedComm 2022;3. [DOI: 10.1002/mco2.167] [Reference Citation Analysis]
|
| 13 |
Tukhvatulin AI, Gordeychuk IV, Dolzhikova IV, Dzharullaeva AS, Krasina ME, Bayurova EO, Grousova DM, Kovyrshina AV, Kondrashova AS, Avdoshina DV, Gulyaev SA, Gulyaeva TV, Moroz AV, Illarionova VV, Zorkov ID, Iliukhina AA, Shelkov AY, Botikov AG, Erokhova AS, Shcheblyakov DV, Esmagambetov IB, Zubkova OV, Tokarskaya EA, Savina DM, Vereveyko YR, Ungur AS, Naroditsky BS, Ishmukhametov AA, Logunov DY, Gintsburg AL. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. Emerging Microbes & Infections. [DOI: 10.1080/22221751.2022.2119169] [Reference Citation Analysis]
|
| 14 |
Agarwal RN, Aggarwal R, Nandarapu P, Aggarwal H, Verma A, Haque A, Tripathi MK. COVID-19 Vaccination Drive in a Low-Volume Primary Care Clinic: Challenges & Lessons Learned in Using Homegrown Self-Scheduling Web-Based Mobile Platforms. Vaccines 2022;10:1072. [DOI: 10.3390/vaccines10071072] [Reference Citation Analysis]
|
| 15 |
Zhang C, Yang M. Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules. Int J Mol Sci 2022;23. [PMID: 35682761 DOI: 10.3390/ijms23116083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 16 |
Dhawan M, Emran TB, Priyanaka, Choudhary OP. Immunomodulatory effects of zinc and its impact on COVID-19 severity. Ann Med Surg (Lond) 2022;77:103638. [PMID: 35464610 DOI: 10.1016/j.amsu.2022.103638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Dhawan M, Emran TB, Choudhary OP. Implications of COVID-19 vaccine boosters amid the emergence of novel variants of SARS-CoV-2. Annals of Medicine and Surgery 2022;77:103612. [DOI: 10.1016/j.amsu.2022.103612] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 18 |
Chavda VP, Vuppu S, Mishra T, Kamaraj S, Patel AB, Sharma N, Chen ZS. Recent review of COVID-19 management: diagnosis, treatment and vaccination. Pharmacol Rep 2022;74:1120-48. [PMID: 36214969 DOI: 10.1007/s43440-022-00425-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
